AI Article Synopsis
Article Abstract
Background: Proton minibeam radiation therapy (pMBRT) is a new radiotherapy approach that has shown a significant increase in the therapeutic window in glioma-bearing rats compared to conventional proton therapy. Such preclinical results encourage the preparation of clinical trials.
Purpose: In this study, the potential of pMBRT for treating clinical indications candidates for the first clinical trials (i.e., brain, lung, and liver metastases) was evaluated.
Methods: Four clinical cases, initially treated with stereotactic radiotherapy (SRT), were selected for this study. pMBRT, SRT, and conventional proton therapy (PT) dose distributions were compared by using three main criteria: (i) the tumor coverage, (ii) the mean dose to organs-at-risk, and (iii) the possible adverse effects in normal tissues by considering valley doses as the responsible for tissue sparing. pMBRT plans consisted of one fraction and one-two fields. Dose calculations were computed by means of Monte Carlo simulations.
Results: pMBRT treatments provide a similar or superior target coverage than SRT, even using fewer fields. pMBRT also significantly reduces the biologically effective dose (BED) to organs-at-risk. In addition, valley and mean doses to normal tissues remain below tolerance limits when treatments are delivered in a single fraction, contrary to PT treatments.
Conclusions: This work provides a first insight into the possibility of treating metastases with pMBRT. More favorable dose distributions and treatment delivery regimes may be expected from this new approach than SRT. The advantages of pMBRT would need to be confirmed by means of Phase I clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mp.16203 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Challenges for the Implementation of Primary Standard Dosimetry in Proton Minibeam Radiation Therapy.
Cancers (Basel)
November 2024
Radiotherapy and Radiation Dosimetry, National Physical Laboratory, Teddington TW11 0LW, UK.
: Spatial fractionation of proton fields as sub-millimeter beamlets to treat cancer has shown better sparing of healthy tissue whilst maintaining the same tumor control. It is critical to ensure primary standard dosimetry is accurate and ready to support the modality's clinical implementation. : This work provided a proof-of-concept, using the National Physical Laboratory's Primary Standard Proton Calorimeter (PSPC) to measure average absorbed dose-to-water in a pMBRT field.
View Article and Find Full Text PDFMulti-collimator proton minibeam radiotherapy with joint dose and PVDR optimization.
Med Phys
November 2024
Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Background: The clinical translation of proton minibeam radiation therapy (pMBRT) presents significant challenges, particularly in developing an optimal treatment planning technique. A uniform target dose is crucial for maximizing anti-tumor efficacy and facilitating the clinical acceptance of pMBRT. However, achieving a high peak-to-valley dose ratio (PVDR) in organs-at-risk (OAR) is essential for sparing normal tissue.
View Article and Find Full Text PDFMonte Carlo modeling of a commercial machine and experimental setup for FLASH-minibeam irradiations with electrons.
Med Phys
November 2024
Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, Orsay, France.
Background: Ultra-high dose rate (UHDR/FLASH) irradiations, along with particle minibeam therapy (PMBT) are both emerging as promising alternatives to current radiotherapy techniques thanks to their improved healthy tissue sparing and similar tumor control.
Purpose: Monte Carlo (MC) modeling of a commercial machine delivering 5-7 MeV electrons at UHDR. This model was used afterward to compare measurements against simulations for an experimental setup combining both FLASH and PMBT modalities.
The significance of dose heterogeneity on the anti-tumor response of minibeam radiation therapy.
Radiother Oncol
December 2024
Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France. Electronic address:
Article Synopsis
- Proton Minibeam Radiation Therapy (pMBRT) is a unique technique that modulates radiation dose delivery to potentially enhance anti-tumor immune responses while impacting treatment outcomes through specific dosimetric parameters like peak and valley doses.* -
- The study used an orthotopic rat model of glioblastoma to explore how different pMBRT configurations influence survival and immune response, finding that higher dose heterogeneity and maintaining a minimum valley dose improved overall outcomes.* -
- Results indicated that optimizing both peak doses and valley doses led to better tumor eradication and less immunosuppression, contrasting with traditional proton therapy that usually creates uniform dose distributions.*
First test beam of the DMAPS-based proton tracker at the pMBRT facility at the Curie Institute.
Phys Med Biol
October 2024
Orsay Proton Therapy Center, Institut Curie, Orsay, France.
Proton radiotherapy's efficacy relies on an accurate relative stopping power (RSP) map of the patient to optimise the treatment plan and minimize uncertainties. Currently, a conversion of a Hounsfield Units map obtained by a common x-ray computed tomography (CT) is used to compute the RSP. This conversion is one of the main limiting factors for proton radiotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!